SlideShare a Scribd company logo
1 of 100
Surviving Sepsis Campaign
Guidelines for Management of
Severe Sepsis/Septic Shock
An Overview
Surviving Sepsis
A global program to:
Reduce mortality rates in severe sepsis
Phase 1 Barcelona declaration
Phase 2 Evidence based guidelines
Phase 3 Implementation and education
Surviving Sepsis
Phase 1 Barcelona declaration
Phase 2 Evidence based guidelines
Phase 3 Implementation and education
Surviving Sepsis
Sponsoring Organizations
 American Association of Critical Care Nurses
 American College of Chest Physicians
 American College of Emergency Physicians
 American Thoracic Society
 Australian and New Zealand Intensive Care Society
 European Society of Clinical Microbiology and Infectious
Diseases
 European Society of Intensive Care Medicine
 European Respiratory Society
 International Sepsis Forum
 Society of Critical Care Medicine
 Surgical Infection Society
Guidelines Committee*
Dellinger (RP)
Carlet
Masur
Gerlach
Levy
Vincent
Calandra
Cohen
Gea-Banacloche
Keh
Marshall
Parker
Harvey
Hazelzet
Hollenberg
Jorgensen
Maier
Maki
Marini
Opal
Osborn
Parrillo
Rhodes
Sevransky
Ramsay
Zimmerman
Beale
Bonten
Brun-Buisson
Carcillo
Cordonnier
Dellinger (EP)
Dhainaut
Finch
Finfer
Fourrier
Sprung
Torres
Vendor
Bennet
Bochud
Cariou
Murphy
Nitsun
Szokol
Trzeciak
Visonneau
*Primary investigators from recently performed positive trials with implications for
septic patients excluded from committee selection.
Surviving Sepsis Campaign (SSC)
Guidelines for Management of Severe
Sepsis and Septic Shock
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T,
Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker
MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM and
the
SSC Management Guidelines Committee
Crit Care Med 2004;32:858-873
Intensive Care Med 2004;30:536-555
available online at
www.springerlink.com
www.sccm.org
www.sepsisforum.com
Sackett DL. Chest 1989; 95:2S–4S
Sprung CL, Bernard GR, Dellinger RP. Intensive Care Medicine 2001; 27(Suppl):S1-S2
Clarifications
Recommendations grouped by category
and not by hierarchy
Grading of recommendation implies
literature support and not priority of
importance
Initial Resuscitation
Figure B, page 948, reproduced with permission from Dellinger RP. Cardiovascular
management of septic shock. Crit Care Med 2003;31:946-955.
The Importance of Early Goal-Directed
Therapy for Sepsis Induced Hypoperfusion
Adapted from Table 3, page 1374, with permission from Rivers E, Nguyen B, Havstad S, et al.
Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med
2001; 345:1368-1377
In-hospital
mortality
(all
patients)
0
10
20
30
40
50
60 Standard therapy
EGDT
28-day
mortality
60-day
mortality
Mortality(%)
Initial Resuscitation
 In the presence of sepsis-induced
hypoperfusion
 Hypotension
 Lactic acidosis
MAP
Urinary
output (mL) 49 +18 56 + 21 43 +13 .60/.71
Capillary blood flow
(mL/min/100 g) 6.0 + 1.6 5.8 + 11 5.3 + 0.9 .59/.55
Red Cell
Velocity (au) 0.42 + 0.06 0.44 +016 0.42 + 0.06 .74/.97
Pico2 (mm Hg) 41 + 2 47 + 2 46 + 2 .11/.12
Pa-Pico2 (mm Hg) 13 + 3 17 + 3 16 + 3 .27/.40
75 mm Hg65 mm Hg 85 mm Hg F/LT
Adapted from Table 4, page 2731, with permission from LeDoux, Astiz ME, Carpati CM,
Rackow ED. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care
Med 2000; 28:2729-2732
Initial Resuscitation
Goals during first 6 hours:
 Central venous pressure: 8–12 mm Hg
 Mean arterial pressure ≥ 65 mm Hg
 Urine output ≥ 0.5 mL kg-1
/hr-1
 Central venous (superior vena cava) or
mixed venous oxygen [SvO2] saturation ≥
70%
Grade B
Initial Resuscitation
Goals during first 6 hours:
 Central venous or mixed venous O2 sat
70% after CVP of 8–12 mm Hg
• Packed RBCs to Hct 30%
• Dobutamine to max 20 µg/kg/min
Grade B
Diagnosis
 Appropriate cultures
 Minimum 2 blood cultures
• 1 percutaneous
• 1 from each vascular access ≥ 48
hrs
Grade D
Antibiotic Therapy
 Begin intravenous antibiotics within
first hour of recognition of severe
sepsis.
Grade E
Antibiotic Therapy
 One or more drugs active against likely
bacterial or fungal pathogens.
 Consider microorganism susceptibility
patterns in the community and hospital.
Grade D
Antibiotic Therapy
Reassess antimicrobial regimen
at 48-72 hrs
• Microbiologic and clinical data
• Narrow-spectrum antibiotics
• Non-infectious cause identified
• Prevent resistance, reduce toxicity,
reduce costs
Grade E
Source Control
 Evaluate patient for a focused infection
amendable to source control measures
including abscess drainage or tissue
debridement.
• Move rapidly
• Consider physiologic upset of measure
• Intravascular access devices
Grade E
Photograph used with permission from Janice L. Zimmerman, MD
EKG tracing reproduced with permission from Janice L. Zimmerman, MD
Fluid Therapy
 Fluid resuscitation may consist of natural or
artificial colloids or crystalloids.
Grade C
Figure 2, page 206, reproduced with permission from Choi PT, Yip G, Quinonez L, Cook DJ.
Crystalloids vs. colloids in fluid resuscitation: A systematic review. Crit Care Med 1999; 27:200–210
Fluid Therapy
 Fluid challenge over 30 min
• 500–1000 ml crystalloid
• 300–500 ml colloid
 Repeat based on response
and tolerance
Grade E
Vasopressors
 Either norepinephrine or dopamine
administered through a central
catheter is the initial vasopressor of
choice.
• Failure of fluid resuscitation
• During fluid resuscitation
Grade D
Effects of Dopamine, Norepinephrine,
and Epinephrine on the Splanchnic
Circulation in Septic Shock
Figure 2, page 1665, reproduced with permission from De Backer D, Creteur J, Silva E, Vincent
JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in
septic shock: Which is best? Crit Care Med 2003; 31:1659-1667
Vasopressors
 Do not use low-dose dopamine for
renal protection.
Grade B
Bellomo R, et al. Lancet 2000; 356:2139-2143
Vasopressors
 In patients requiring vasopressors,
place an arterial catheter as soon as
possible.
Grade E
Circulating Vasopressin Levels in Septic Shock
Figure 2, page 1755 reproduced with permission from Sharshar T, Blanchard A, Paillard
M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758
Vasopressin and Septic Shock
• Versus cardiogenic shock
• Decreases or eliminates
requirements of traditional
pressors
• As a pure vasopressor expected
to decrease cardiac output
Vasopressors
Vasopressin
Not a replacement for norepinephrine or
dopamine as a first-line agent
Consider in refractory shock despite high-
dose conventional vasopressors
If used, administer at 0.01-0.04 units/minute
in adults
Grade E
During Septic Shock
10 Days Post Shock
Diastole Systole
Diastole Systole
Images used with permission from Joseph E. Parrillo, MD
Inotropic Therapy
 Consider dobutamine in patients with
measured low cardiac output despite
fluid resuscitation.
 Continue to titrate vasopressor to mean
arterial pressure of 65 mm Hg or greater.
Grade E
Inotropic Therapy
 Do not increase cardiac index to achieve
an arbitrarily predefined elevated level of
oxygen delivery.
Grade A
Yu, et al. CCM 1993; 21:830-838
Hayes, et al. NEJM 1994; 330-1717-1722
Gattinoni, et al. NEJM 1995; 333:1025-1032
Figure 2A, page 867, reproduced with permission from Annane D, Sébille V, Charpentier C, et
al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in
patients with septic shock. JAMA 2002; 288:862-871
Steroid Therapy
P = .045
Figure 2 and Figure 3, page 648, reproduced with permission from
Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic
shock with supraphysiologic doses of hydrocortisone. Crit Care
Med 1998; 26:645-650
Figure 2 and Figure 3, page 727, reproduced with permission from
Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone
reverse hyperdynamic septic shock: A prospective, randomized,
double-blind, single-center study. Crit Care Med 1999; 27:723-732
P = .007
Annane, Bollaert and Briegel
 Different doses, routes of administration
and stopping/tapering rules
Annane
 Required hypotension despite
therapeutic intervention
Bollaert and Briegel
 Required vasopressor support only
Steroids
 Treat patients who still require
vasopressors despite fluid
replacement with hydrocortisone
200-300 mg/day, for 7 days in
three or four divided doses or by
continuous infusion.
Grade C
Figure 2B, page 867, reproduced with permission from Annane D, Sébille V, Charpentier C, et al.
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients
with septic shock. JAMA 2002; 288:862-871
Identification of
Relative Adrenal Insufficiency
Recommendations vary based on
different measurements and different
cut-off levels
 Peak cortisol after stimulation
 Random cortisol
 Incremental increase after stimulation
 Lower dose ACTH stimulation test
 Combinations of these criteria
Steroids
Optional:
 Adrenocorticotropic hormone
(ACTH) stimulation test (250-µg)
Continue treatments only in
nonresponders (rise in
cortisol ≤9 µg/dl)
Grade E
Dexamethasone and
Cortisol Assay
Steroids
Optional:
 Decrease steroid dose if septic
shock resolves.
Grade E
Steroids
Optional:
 Taper corticosteroid dose at
end of therapy.
Grade E
Immunologic and Hemodynamic Effects
of “Low-Dose” Hydrocortisone in Septic Shock
Figure 3, page 515, reproduced with permission from Keh D, Boehnke T, Weber-
Cartens S, et al. Immunologic and hemodynamic effects of “low dose” hydrocortisone
in septic shock. Am J Respir Crit Care Med 2003;167:512-520
Steroids
Optional:
 Add fludrocortisone (50 µg orally
once a day) to this regimen.
Grade E
ADRENALS AND SURVIVAL
FROM ENDOTOXEMIA
0
10
20
30
40
50
60
70
80
90
INTACT SHAM ADRNX MEDX
DEATH %
Adapted from Figure 7, page 437, with permission from Witek-Janusek L, Yelich MR.
Role of the adrenal cortex and medulla in the young rats’ glucoregulatory response
to endotoxin. Shock 1995; 3:434-439
Steroids
 Do not use corticosteroids >300
mg/day of hydrocortisone to treat
septic shock.
Grade A
Bone, et al. NEJM 1987; 317-658
VA Systemic Sepsis Cooperative Study Group. NEJM 1987; 317:659-665
Thrombin
Thrombomodulin
Protein
C (Inactive)
Protein C Activity
Blood Vessel
Blood Flow ⇒
Protein C
Receptor
Protein
S
Human Activated Protein C
Endogenous Regulator of Coagulation
35
30
25
20
15
10
5
0
30.8%
24.7%
Placebo
(n-840)
Drotrecogin
alfa
(activated)
(n=850)
Mortality(%)
6.1% absolute
reduction in
mortality
Results: 28-Day All-Cause Mortality
Primary analysis results
2-sided p-value 0.005
Adjusted relative risk reduction 19.4%
Increase in odds of survival 38.1%
Adapted from Table 4, page 704, with permission from Bernard GR, Vincent JL, Laterre PF, et al.
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med
2001; 344:699-709
Patient Selection for rhAPC
 Full support patient
 Infection induced organ/system
dysfunction
 High risk of death
 No absolute contraindications
Mortality and APACHE II Quartile
APACHE II Quartile
*Numbers above bars indicate total deaths
0
5
10
15
20
25
30
35
40
45
50
1st (3-19) 2nd (20-24) 3rd (25-29) 4th (30-53)
Placebo
Drotrecogin
Mortality(percent)
26:33
57:49
58:48
118:80
Adapted from Figure 2, page S90, with permission from Bernard GR. Drotrecogin alfa (activated)
(recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003;
31[Suppl.]:S85-S90
Mortality and Numbers of Organs Failing
Percent
Mortality
0
10
20
30
40
50
60
1 2 3 4 5
Placebo
Drotrecogin
Number of Organs Failing at Entry
Adapted from Figure 4, page S91, with permission from Bernard GR. Drotrecogin alfa (activated)
(recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003;
31[Suppl.]:S85-S90
Recombinant Human Activated
Protein C (rhAPC)
 High risk of death
 APACHE II ≥ 25
 Sepsis-induced multiple organ failure
 Septic shock
 Sepsis induced ARDS
 No absolute contraindications
 Weigh relative contraindications
Grade B
Transfusion Strategy
in the Critically Ill
Figure 2A, page 414, reproduced with permission from Hebert PC, Wells G, Blajchman MA, et al. A multicenter,
randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417
Blood Product Administration
Red Blood Cells
Tissue hypoperfusion resolved
No extenuating circumstances
 Coronary artery disease
 Acute hemorrhage
 Lactic acidosis
Transfuse < 7.0 g/dl to maintain 7.0-9.0 g/dL
Grade B
Blood Product Administration
 Do not use erythropoietin to treat sepsis-
related anemia. Erythropoietin may be
used for other accepted reasons.
Grade B
Blood Product Administration
Fresh frozen plasma
• Bleeding
• Planned invasive procedures.
Grade E
Blood Product Administration
• Do not use antithrombin therapy.
Grade B
Warren et al. JAMA 2001; 1869-1878
Blood Product Administration
 Platelet administration
 Transfuse for < 5000/mm3 -
 Transfuse for 5000/mm3
– 30,000/mm3
with
significant bleeding risk
 Transfuse < 50,000/mm3
for invasive
procedures or bleeding
Grade E
Mechanical Ventilation of
Sepsis-Induced ALI/ARDS
0
5
10
15
20
25
30
35
40
6 ml/kg
12 ml/kg
%Mortality
ARDSnet Mechanical Ventilation Protocol
Results: Mortality
Adapted from Figure 1, page 1306, with permission from The Acute Respiratory Distress
Syndrome Network. N Engl J Med 2000;342:1301-1378
Peak Airway
Pressure
Inspiratory Plateau
Pressure
PEEP (5 cm
H2O
5
0
Mechanical Ventilation of
Sepsis-Induced ALI/ARDS
Reduce tidal volume over 1–2 hrs
to 6 ml/kg predicted body weight
Maintain inspiratory plateau
pressure < 30 cm H20
Grade B
Mechanical Ventilation of
Sepsis-Induced ALI/ARDS
 Minimum PEEP
 Prevent end expiratory lung
collapse
 Setting PEEP
 FIO2 requirement
 Thoracopulmonary compliance
Grade E
The Role of Prone Positioning in ARDS
 70% of prone
patients improved
oxygenation
 70% of response
within 1 hour
 10-day mortality rate in
quartile with lowest
PaO2:FIO2 ratio (≤88)
 Prone —
23.1%
 Supine – 47.2%
Gattinoni L, et al. N Engl J Med 2001;345:568-73; Slutsky AS. N Engl J Med 2001;345:610-2.
Kaplan-Meier estimates
of
survival at 6 months
Survival(%)
100
75
50
25
0
30 60 90 120 150 1800
Days
Supine group
Prone group
P=0.65
The Role of Prone Positioning in ARDS
Consider prone positioning in ARDS when:
 Potentially injurious levels of F1O2 or
plateau pressure exist
 Not at high risk from positional changes
Grade E
Mechanical Ventilation
of Severe Sepsis
 Semirecumbent position unless
contraindicated with head of the bed
raised to 45o
Grade C
Drakulovic et al. Lancet 1999; 354:1851-1858
Mechanical Ventilation
of Septic Patients
 Use weaning protocol and a
spontaneous breathing trial (SBT),
at least daily
Grade A
Ely, et al. NEJM 1996; 335:1864-1869
Esteban, et al. AJRCCM 1997; 156:459-465
Esteban, et al. AJRCCM 1999; 159:512-518
Mechanical Ventilation
of Septic Patients
SBT options
• Low level of pressure support
with continuous positive airway
pressure 5 cm H2O
• T-piece
Prior to SBT
a) Arousable
b) Hemodynamically stable (without
vasopressor agents)
c) No new potentially serious conditions
d) Low ventilatory and end-expiratory
pressure requirements
e) Requiring levels of FIO2 that could be
safely delivered with a face mask or
nasal cannula
Consider extubation if SBT is unsuccessful
Sedation and Analgesia in Sepsis
 Sedation protocol for mechanically
ventilated patients with standardized
subjective sedation scale target.
• Intermittent bolus
• Continuous infusion with daily
awakening/retitration
Grade B
Kollef, et al. Chest 1998; 114:541-548
Brook, et al. CCM 1999; 27:2609-2615
Kress, et al. NEJM 2000; 342:1471-1477
Neuromuscular Blockers
Avoid if possible
Used longer than 2-3 hrs
 PRN bolus
 Continuous infusion with twitch monitor
Grade E
The Role of Intensive
Insulin Therapy in the Critically Ill
At 12 months, intensive insulin
therapy reduced mortality by
3.4% (P<0.04)
Adapted from Figure 1B, page 1363, with permission from van den Berghe G, Wouters P,
Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67
In-hospitalsurvival(%)
100
0
0
Intensive treatment
Conventional treatment
Days after admission
80
84
88
92
96
50 100 150 200 250
P=0.01
Glucose Control
 After initial stabilization
 Glucose < 150 mg/dL
 Continuous infusion insulin and glucose
or feeding (enteral preferred)
 Monitoring
• Initially q30–60 mins
• After stabilization q4h
Grade D
Renal Replacement
Absence of hemodynamic instability
 Intermittent hemodialysis and
continuous venovenous filtration equal
(CVVH)
Hemodynamic instability
 CVVH preferred
Grade B
 Bicarbonate therapy not recommended to
improve hemodynamics in patients with
lactate induced pH >7.15
Grade C
Cooper, et al. Ann Intern Med 1990; 112:492-498
Mathieu, et al. CCM 1991; 19:1352-1356
Bicarbonate Therapy
Changing pH Has Limited Value
Treatment Before After
NaHCO3 (2 mEq/kg)
pH 7.22 7.36
PAOP 15 17
Cardiac output 6.7 7.5
0.9% NaCl
pH 7.24 7.23
PAOP 14 17
Cardiac output 6.6 7.3
Cooper DJ, et al. Ann Intern Med 1990; 112:492-498
Deep Vein Thrombosis Prophylaxis
Heparin (UH or LMWH)
Contraindication for heparin
 Mechanical device (unless contraindicated)
High risk patients
 Combination pharmacologic and mechanical
Grade A
Primary Stress Ulcer Risk Factors
Frequently Present in Severe Sepsis
Mechanical ventilation
Coagulopathy
Hypotension
Choice of Agents for
Stress Ulcer Prophylaxis
H2 receptor blockers
Role of proton pump inhibitors
Grade C
Cook DJ, et al. Am J Med 1991; 91:519-527
Consideration for
Limitation of Support
 Advance care planning, including the
communication of likely outcomes and
realistic goals of treatment, should be
discussed with patients and families.
Decisions for less aggressive support
or withdrawal of support may be in the
patient’s best interest.
Grade E
Phase 1 Barcelona declaration
Phase 2 Evidence based guidelines Paediatric issues
Phase 3 Implementation and education
Surviving Sepsis
Fluid Resuscitation
Aggressive fluid resuscitation with boluses
of 20 ml/kg over 5-10 min
Blood pressure by itself is not a reliable
endpoint for resuscitation
Initial resuscitation usually requires 40-60
ml/kg, but more may be required
Hemodynamic Support
 Hemodynamic profile may be variable
 Dopamine for hypotension
 Epinephrine or norepinephrine for dopamine-
refractory shock
 Dobutamine for low cardiac output state
 Inhaled NO useful in neonates with post-partum
pulmonary hypertension and sepsis
Therapeutic Endpoints
 Capillary refill < 2 sec
 Warm extremities
 Urine output > 1 ml/kg/hr
 Normal mental status
 Decreased lactate
 Central venous O2 saturation > 70%
Other Therapies
 Steroids: recommended for children with
catecholamine resistance and suspected or
proven adrenal insufficiency.
 Activated protein C not studied adequately in
children yet.
 GM-CSF shown to be of benefit in neonates
with sepsis and neutropenia.
 Extracorporeal membrane oxygenation
(ECMO) may be considered in children with
refractory shock or respiratory failure.
Phase 1 Barcelona declaration
Phase 2 Evidence based guideline
Phase 3 Implementation and education
Surviving Sepsis
Sepsis Resuscitation Bundle
Serum lactate measured
Blood cultures obtained prior to
antibiotic administration
From the time of presentation, broad-
spectrum antibiotics administered
within 3 hours for ED admissions and
1 hour for non-ED ICU admissions
Sepsis Resuscitation Bundle
In the event of hypotension and/or
lactate >4 mmol/L (36 mg/dl):
 Deliver an initial minimum of 20 ml/kg of
crystalloid (or colloid equivalent*)
 Apply vasopressors for hypotension not
responding to initial fluid resuscitation to
maintain mean arterial pressure (MAP) ≥65
mm Hg
*See the individual chart measurement tool for an equivalency chart.
Sepsis Management Bundle
Low-dose steroids* administered for
septic shock in accordance with a
standardized ICU policy
Drotrecogin alfa (activated)
administered in accordance with a
standardized ICU policy
*See the individual chart measurement tool for an equivalency chart.
Sepsis Management Bundle
 Glucose control maintained ≥ lower limit
of normal, but < 150 mg/dl (8.3 mmol/L)
 Inspiratory plateau pressures maintained
< 30 cm H2O for mechanically ventilated
patients.
Sepsis Resuscitation Bundle
In the event of persistent hypotension
despite fluid resuscitation (septic
shock) and/or lactate > 4 mmol/L (36
mg/dl):
 Achieve central venous pressure (CVP) of
8 mm Hg
 Achieve central venous oxygen saturation
(ScvO2) of ≥ 70%**
**Achieving a mixed venous oxygen saturation (SvO2) of 65% is an acceptable
alternative.
A clinician, armed with the sepsis bundles, attacks the three heads of severe
sepsis: hypotension, hypoperfusion and organ dysfunction. Crit Care Med 2004;
320(Suppl):S595-S597
Actual title of painting is “Hercules Kills
Cerberus,” by Renato Pettinato, 2001.
Painting hangs in Zuccaro Place in Agira,
Sicily, Italy. Used with permission of artist
and the Rubolotto family.
www.survivingsepsis.org
♦♦♦
www.IHI.org
Acknowledgment
The SSC is grateful to R. Phillip
Dellinger, MD, for his input into
creation of this slide kit.

More Related Content

What's hot

Sepsis &amp; septic shock an updated management
Sepsis &amp; septic shock an updated managementSepsis &amp; septic shock an updated management
Sepsis &amp; septic shock an updated managementahad80a
 
Surviving Sepsis Campaign- International guidelines for management of sepsis ...
Surviving Sepsis Campaign- International guidelines for management of sepsis ...Surviving Sepsis Campaign- International guidelines for management of sepsis ...
Surviving Sepsis Campaign- International guidelines for management of sepsis ...Dr.Mahmoud Abbas
 
Severe Sepsis & Septic Shock
Severe Sepsis & Septic ShockSevere Sepsis & Septic Shock
Severe Sepsis & Septic ShockAndrew Ferguson
 
Sepsis - Process and Scale - Daniels
Sepsis - Process and Scale - DanielsSepsis - Process and Scale - Daniels
Sepsis - Process and Scale - Danielsintensivecaresociety
 
Approach to sepsis- a primary physician perspective
Approach to sepsis- a primary physician perspectiveApproach to sepsis- a primary physician perspective
Approach to sepsis- a primary physician perspectiveNaveen Kumar
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shockmahadev deuja
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shockBabak Jebelli
 
Management of septic shock
Management of septic shockManagement of septic shock
Management of septic shockDrsaketmittal
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shockmadhushah6
 
Sepsis power point presentation
Sepsis power point presentationSepsis power point presentation
Sepsis power point presentationdlecolst
 
Sepsis: ED and Trauma symposium
Sepsis: ED and Trauma symposiumSepsis: ED and Trauma symposium
Sepsis: ED and Trauma symposiumUFJaxEMS
 
The Sepsis Resuscitation And Management Bundles
The Sepsis Resuscitation And Management BundlesThe Sepsis Resuscitation And Management Bundles
The Sepsis Resuscitation And Management BundlesBilal Baig
 
Surviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines UpdatedSurviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines UpdatedSun Yai-Cheng
 
Management of septic shock
Management of septic shockManagement of septic shock
Management of septic shockEsteban Salazar
 
Care of the patient in severe sepsis septic shock nursing inservice 2012
Care of the patient in severe sepsis septic shock nursing inservice 2012Care of the patient in severe sepsis septic shock nursing inservice 2012
Care of the patient in severe sepsis septic shock nursing inservice 2012mgrexx
 

What's hot (20)

Sepsis &amp; septic shock an updated management
Sepsis &amp; septic shock an updated managementSepsis &amp; septic shock an updated management
Sepsis &amp; septic shock an updated management
 
Surviving Sepsis Campaign- International guidelines for management of sepsis ...
Surviving Sepsis Campaign- International guidelines for management of sepsis ...Surviving Sepsis Campaign- International guidelines for management of sepsis ...
Surviving Sepsis Campaign- International guidelines for management of sepsis ...
 
Severe Sepsis & Septic Shock
Severe Sepsis & Septic ShockSevere Sepsis & Septic Shock
Severe Sepsis & Septic Shock
 
Sepsis lecture 2015 slide share
Sepsis lecture 2015 slide shareSepsis lecture 2015 slide share
Sepsis lecture 2015 slide share
 
Septic shock
Septic shockSeptic shock
Septic shock
 
Sepsis - Process and Scale - Daniels
Sepsis - Process and Scale - DanielsSepsis - Process and Scale - Daniels
Sepsis - Process and Scale - Daniels
 
Septic shock
Septic shockSeptic shock
Septic shock
 
Approach to sepsis- a primary physician perspective
Approach to sepsis- a primary physician perspectiveApproach to sepsis- a primary physician perspective
Approach to sepsis- a primary physician perspective
 
Severe Sepsis And Septic Shock
Severe Sepsis And Septic ShockSevere Sepsis And Septic Shock
Severe Sepsis And Septic Shock
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
 
Management of septic shock
Management of septic shockManagement of septic shock
Management of septic shock
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
 
Sepsis power point presentation
Sepsis power point presentationSepsis power point presentation
Sepsis power point presentation
 
Sepsis: ED and Trauma symposium
Sepsis: ED and Trauma symposiumSepsis: ED and Trauma symposium
Sepsis: ED and Trauma symposium
 
The Sepsis Resuscitation And Management Bundles
The Sepsis Resuscitation And Management BundlesThe Sepsis Resuscitation And Management Bundles
The Sepsis Resuscitation And Management Bundles
 
Surviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines UpdatedSurviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines Updated
 
Management of septic shock
Management of septic shockManagement of septic shock
Management of septic shock
 
Notes for Differences in Anesthesia
Notes for Differences in Anesthesia Notes for Differences in Anesthesia
Notes for Differences in Anesthesia
 
Care of the patient in severe sepsis septic shock nursing inservice 2012
Care of the patient in severe sepsis septic shock nursing inservice 2012Care of the patient in severe sepsis septic shock nursing inservice 2012
Care of the patient in severe sepsis septic shock nursing inservice 2012
 

Similar to Sepsis guidlines

Optimzing sepsis management
Optimzing sepsis managementOptimzing sepsis management
Optimzing sepsis managementEM OMSB
 
Jeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.pptJeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.pptdrram666
 
sepsis and septic shock guidelines[12585].pptx
sepsis and septic shock  guidelines[12585].pptxsepsis and septic shock  guidelines[12585].pptx
sepsis and septic shock guidelines[12585].pptxalmawali10
 
sepsis and septic shock guidelines[12585].pptx
sepsis and septic shock  guidelines[12585].pptxsepsis and septic shock  guidelines[12585].pptx
sepsis and septic shock guidelines[12585].pptxalmawali10
 
Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015Jon Sweet
 
sepsis 2019.pdf
sepsis 2019.pdfsepsis 2019.pdf
sepsis 2019.pdfzahid aziz
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenNBCA
 
arterial health in hypertension
 arterial health in hypertension arterial health in hypertension
arterial health in hypertensionKyaw Win
 
IV%20FLUIDS.pptx
IV%20FLUIDS.pptxIV%20FLUIDS.pptx
IV%20FLUIDS.pptxArunHM3
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failuredrucsamal
 
Cilostazol treatment intermittent claudication
Cilostazol   treatment intermittent claudicationCilostazol   treatment intermittent claudication
Cilostazol treatment intermittent claudicationKaloyan Stamenov
 
Management of severe sepsis & septic shock f
Management of severe sepsis & septic shock  fManagement of severe sepsis & septic shock  f
Management of severe sepsis & septic shock fDMCH
 
ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change taem
 
Sepsis modern day killer
Sepsis modern day killerSepsis modern day killer
Sepsis modern day killerPrashant Nasa
 
8 Severe Acute Pancreatitis
8 Severe Acute Pancreatitis8 Severe Acute Pancreatitis
8 Severe Acute PancreatitisDang Thanh Tuan
 

Similar to Sepsis guidlines (20)

Optimzing sepsis management
Optimzing sepsis managementOptimzing sepsis management
Optimzing sepsis management
 
Jeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.pptJeff_Pulm_CC__grand_rounds_2011.ppt
Jeff_Pulm_CC__grand_rounds_2011.ppt
 
Acute Heart Failure
Acute Heart FailureAcute Heart Failure
Acute Heart Failure
 
sepsis and septic shock guidelines[12585].pptx
sepsis and septic shock  guidelines[12585].pptxsepsis and septic shock  guidelines[12585].pptx
sepsis and septic shock guidelines[12585].pptx
 
sepsis and septic shock guidelines[12585].pptx
sepsis and septic shock  guidelines[12585].pptxsepsis and septic shock  guidelines[12585].pptx
sepsis and septic shock guidelines[12585].pptx
 
Sepsis 3
Sepsis 3Sepsis 3
Sepsis 3
 
Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015Hospital Medicine Update, VA ACP Meeting 2015
Hospital Medicine Update, VA ACP Meeting 2015
 
sepsis 2019.pdf
sepsis 2019.pdfsepsis 2019.pdf
sepsis 2019.pdf
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
 
Bundle of sepsis
Bundle of sepsisBundle of sepsis
Bundle of sepsis
 
arterial health in hypertension
 arterial health in hypertension arterial health in hypertension
arterial health in hypertension
 
Sepsis
SepsisSepsis
Sepsis
 
IV%20FLUIDS.pptx
IV%20FLUIDS.pptxIV%20FLUIDS.pptx
IV%20FLUIDS.pptx
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failure
 
Cilostazol treatment intermittent claudication
Cilostazol   treatment intermittent claudicationCilostazol   treatment intermittent claudication
Cilostazol treatment intermittent claudication
 
Management of severe sepsis & septic shock f
Management of severe sepsis & septic shock  fManagement of severe sepsis & septic shock  f
Management of severe sepsis & septic shock f
 
ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change
 
Sepsis modern day killer
Sepsis modern day killerSepsis modern day killer
Sepsis modern day killer
 
8 Severe Acute Pancreatitis
8 Severe Acute Pancreatitis8 Severe Acute Pancreatitis
8 Severe Acute Pancreatitis
 
Cancer related anemia
Cancer related anemiaCancer related anemia
Cancer related anemia
 

More from Pramod Sarwa

Antiplatelets : target site, evidences, guidelines
Antiplatelets : target site, evidences, guidelines Antiplatelets : target site, evidences, guidelines
Antiplatelets : target site, evidences, guidelines Pramod Sarwa
 
Neonatal resussitation
Neonatal resussitationNeonatal resussitation
Neonatal resussitationPramod Sarwa
 
targetting 100% survival in toxicology cases
targetting 100% survival in toxicology casestargetting 100% survival in toxicology cases
targetting 100% survival in toxicology casesPramod Sarwa
 
Medicolegal aspectsof anaesthesia
Medicolegal aspectsof anaesthesia Medicolegal aspectsof anaesthesia
Medicolegal aspectsof anaesthesia Pramod Sarwa
 
Blood transfusion in pediatrics part1
Blood transfusion in pediatrics  part1Blood transfusion in pediatrics  part1
Blood transfusion in pediatrics part1Pramod Sarwa
 
anesthesia for obstructed inguinal hernia
anesthesia for obstructed inguinal herniaanesthesia for obstructed inguinal hernia
anesthesia for obstructed inguinal herniaPramod Sarwa
 
Anaesthesia for-fetal-surgery
Anaesthesia for-fetal-surgeryAnaesthesia for-fetal-surgery
Anaesthesia for-fetal-surgeryPramod Sarwa
 
anaesthesia for pediatric airway surgery
anaesthesia for pediatric airway surgeryanaesthesia for pediatric airway surgery
anaesthesia for pediatric airway surgeryPramod Sarwa
 
anaesthetic implications of Congenital diaphragmatic-hernia
anaesthetic implications of Congenital diaphragmatic-herniaanaesthetic implications of Congenital diaphragmatic-hernia
anaesthetic implications of Congenital diaphragmatic-herniaPramod Sarwa
 

More from Pramod Sarwa (11)

Icu economics
Icu economicsIcu economics
Icu economics
 
Antiplatelets : target site, evidences, guidelines
Antiplatelets : target site, evidences, guidelines Antiplatelets : target site, evidences, guidelines
Antiplatelets : target site, evidences, guidelines
 
1 op jrccth11
1 op jrccth111 op jrccth11
1 op jrccth11
 
Neonatal resussitation
Neonatal resussitationNeonatal resussitation
Neonatal resussitation
 
targetting 100% survival in toxicology cases
targetting 100% survival in toxicology casestargetting 100% survival in toxicology cases
targetting 100% survival in toxicology cases
 
Medicolegal aspectsof anaesthesia
Medicolegal aspectsof anaesthesia Medicolegal aspectsof anaesthesia
Medicolegal aspectsof anaesthesia
 
Blood transfusion in pediatrics part1
Blood transfusion in pediatrics  part1Blood transfusion in pediatrics  part1
Blood transfusion in pediatrics part1
 
anesthesia for obstructed inguinal hernia
anesthesia for obstructed inguinal herniaanesthesia for obstructed inguinal hernia
anesthesia for obstructed inguinal hernia
 
Anaesthesia for-fetal-surgery
Anaesthesia for-fetal-surgeryAnaesthesia for-fetal-surgery
Anaesthesia for-fetal-surgery
 
anaesthesia for pediatric airway surgery
anaesthesia for pediatric airway surgeryanaesthesia for pediatric airway surgery
anaesthesia for pediatric airway surgery
 
anaesthetic implications of Congenital diaphragmatic-hernia
anaesthetic implications of Congenital diaphragmatic-herniaanaesthetic implications of Congenital diaphragmatic-hernia
anaesthetic implications of Congenital diaphragmatic-hernia
 

Recently uploaded

Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableTrichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableGENUINE ESCORT AGENCY
 
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...jageshsingh5554
 
Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...chandars293
 
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...tanya dube
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In AhmedabadGENUINE ESCORT AGENCY
 
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...GENUINE ESCORT AGENCY
 
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...parulsinha
 
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeCall Girls Delhi
 
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Ishani Gupta
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...hotbabesbook
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...chetankumar9855
 
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service AvailableDipal Arora
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...chandars293
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...khalifaescort01
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...chandars293
 
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...narwatsonia7
 
Call Girls Kurnool Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kurnool Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Kurnool Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kurnool Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...GENUINE ESCORT AGENCY
 

Recently uploaded (20)

Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableTrichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
 
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...
VIP Service Call Girls Sindhi Colony 📳 7877925207 For 18+ VIP Call Girl At Th...
 
Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...Top Rated  Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
Top Rated Hyderabad Call Girls Chintal ⟟ 9332606886 ⟟ Call Me For Genuine Se...
 
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
 
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
 
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
 
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
 
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
 
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
 
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
 
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 9332606886 ⟟ Call Me For Genuine ...
 
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
 
Call Girls Kurnool Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kurnool Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Kurnool Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kurnool Just Call 8250077686 Top Class Call Girl Service Available
 
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
 

Sepsis guidlines

  • 1. Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis/Septic Shock An Overview
  • 2. Surviving Sepsis A global program to: Reduce mortality rates in severe sepsis
  • 3. Phase 1 Barcelona declaration Phase 2 Evidence based guidelines Phase 3 Implementation and education Surviving Sepsis
  • 4. Phase 1 Barcelona declaration Phase 2 Evidence based guidelines Phase 3 Implementation and education Surviving Sepsis
  • 5. Sponsoring Organizations  American Association of Critical Care Nurses  American College of Chest Physicians  American College of Emergency Physicians  American Thoracic Society  Australian and New Zealand Intensive Care Society  European Society of Clinical Microbiology and Infectious Diseases  European Society of Intensive Care Medicine  European Respiratory Society  International Sepsis Forum  Society of Critical Care Medicine  Surgical Infection Society
  • 6. Guidelines Committee* Dellinger (RP) Carlet Masur Gerlach Levy Vincent Calandra Cohen Gea-Banacloche Keh Marshall Parker Harvey Hazelzet Hollenberg Jorgensen Maier Maki Marini Opal Osborn Parrillo Rhodes Sevransky Ramsay Zimmerman Beale Bonten Brun-Buisson Carcillo Cordonnier Dellinger (EP) Dhainaut Finch Finfer Fourrier Sprung Torres Vendor Bennet Bochud Cariou Murphy Nitsun Szokol Trzeciak Visonneau *Primary investigators from recently performed positive trials with implications for septic patients excluded from committee selection.
  • 7. Surviving Sepsis Campaign (SSC) Guidelines for Management of Severe Sepsis and Septic Shock Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM and the SSC Management Guidelines Committee Crit Care Med 2004;32:858-873 Intensive Care Med 2004;30:536-555 available online at www.springerlink.com www.sccm.org www.sepsisforum.com
  • 8. Sackett DL. Chest 1989; 95:2S–4S Sprung CL, Bernard GR, Dellinger RP. Intensive Care Medicine 2001; 27(Suppl):S1-S2
  • 9. Clarifications Recommendations grouped by category and not by hierarchy Grading of recommendation implies literature support and not priority of importance
  • 11. Figure B, page 948, reproduced with permission from Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003;31:946-955.
  • 12. The Importance of Early Goal-Directed Therapy for Sepsis Induced Hypoperfusion Adapted from Table 3, page 1374, with permission from Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377 In-hospital mortality (all patients) 0 10 20 30 40 50 60 Standard therapy EGDT 28-day mortality 60-day mortality Mortality(%)
  • 13. Initial Resuscitation  In the presence of sepsis-induced hypoperfusion  Hypotension  Lactic acidosis
  • 14. MAP Urinary output (mL) 49 +18 56 + 21 43 +13 .60/.71 Capillary blood flow (mL/min/100 g) 6.0 + 1.6 5.8 + 11 5.3 + 0.9 .59/.55 Red Cell Velocity (au) 0.42 + 0.06 0.44 +016 0.42 + 0.06 .74/.97 Pico2 (mm Hg) 41 + 2 47 + 2 46 + 2 .11/.12 Pa-Pico2 (mm Hg) 13 + 3 17 + 3 16 + 3 .27/.40 75 mm Hg65 mm Hg 85 mm Hg F/LT Adapted from Table 4, page 2731, with permission from LeDoux, Astiz ME, Carpati CM, Rackow ED. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000; 28:2729-2732
  • 15. Initial Resuscitation Goals during first 6 hours:  Central venous pressure: 8–12 mm Hg  Mean arterial pressure ≥ 65 mm Hg  Urine output ≥ 0.5 mL kg-1 /hr-1  Central venous (superior vena cava) or mixed venous oxygen [SvO2] saturation ≥ 70% Grade B
  • 16. Initial Resuscitation Goals during first 6 hours:  Central venous or mixed venous O2 sat 70% after CVP of 8–12 mm Hg • Packed RBCs to Hct 30% • Dobutamine to max 20 µg/kg/min Grade B
  • 17. Diagnosis  Appropriate cultures  Minimum 2 blood cultures • 1 percutaneous • 1 from each vascular access ≥ 48 hrs Grade D
  • 18. Antibiotic Therapy  Begin intravenous antibiotics within first hour of recognition of severe sepsis. Grade E
  • 19. Antibiotic Therapy  One or more drugs active against likely bacterial or fungal pathogens.  Consider microorganism susceptibility patterns in the community and hospital. Grade D
  • 20. Antibiotic Therapy Reassess antimicrobial regimen at 48-72 hrs • Microbiologic and clinical data • Narrow-spectrum antibiotics • Non-infectious cause identified • Prevent resistance, reduce toxicity, reduce costs Grade E
  • 21. Source Control  Evaluate patient for a focused infection amendable to source control measures including abscess drainage or tissue debridement. • Move rapidly • Consider physiologic upset of measure • Intravascular access devices Grade E
  • 22. Photograph used with permission from Janice L. Zimmerman, MD
  • 23. EKG tracing reproduced with permission from Janice L. Zimmerman, MD
  • 24. Fluid Therapy  Fluid resuscitation may consist of natural or artificial colloids or crystalloids. Grade C
  • 25. Figure 2, page 206, reproduced with permission from Choi PT, Yip G, Quinonez L, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: A systematic review. Crit Care Med 1999; 27:200–210
  • 26. Fluid Therapy  Fluid challenge over 30 min • 500–1000 ml crystalloid • 300–500 ml colloid  Repeat based on response and tolerance Grade E
  • 27. Vasopressors  Either norepinephrine or dopamine administered through a central catheter is the initial vasopressor of choice. • Failure of fluid resuscitation • During fluid resuscitation Grade D
  • 28. Effects of Dopamine, Norepinephrine, and Epinephrine on the Splanchnic Circulation in Septic Shock Figure 2, page 1665, reproduced with permission from De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med 2003; 31:1659-1667
  • 29. Vasopressors  Do not use low-dose dopamine for renal protection. Grade B Bellomo R, et al. Lancet 2000; 356:2139-2143
  • 30. Vasopressors  In patients requiring vasopressors, place an arterial catheter as soon as possible. Grade E
  • 31. Circulating Vasopressin Levels in Septic Shock Figure 2, page 1755 reproduced with permission from Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758
  • 32. Vasopressin and Septic Shock • Versus cardiogenic shock • Decreases or eliminates requirements of traditional pressors • As a pure vasopressor expected to decrease cardiac output
  • 33. Vasopressors Vasopressin Not a replacement for norepinephrine or dopamine as a first-line agent Consider in refractory shock despite high- dose conventional vasopressors If used, administer at 0.01-0.04 units/minute in adults Grade E
  • 34. During Septic Shock 10 Days Post Shock Diastole Systole Diastole Systole Images used with permission from Joseph E. Parrillo, MD
  • 35. Inotropic Therapy  Consider dobutamine in patients with measured low cardiac output despite fluid resuscitation.  Continue to titrate vasopressor to mean arterial pressure of 65 mm Hg or greater. Grade E
  • 36. Inotropic Therapy  Do not increase cardiac index to achieve an arbitrarily predefined elevated level of oxygen delivery. Grade A Yu, et al. CCM 1993; 21:830-838 Hayes, et al. NEJM 1994; 330-1717-1722 Gattinoni, et al. NEJM 1995; 333:1025-1032
  • 37. Figure 2A, page 867, reproduced with permission from Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871 Steroid Therapy
  • 38. P = .045 Figure 2 and Figure 3, page 648, reproduced with permission from Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-650 Figure 2 and Figure 3, page 727, reproduced with permission from Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-732 P = .007
  • 39. Annane, Bollaert and Briegel  Different doses, routes of administration and stopping/tapering rules Annane  Required hypotension despite therapeutic intervention Bollaert and Briegel  Required vasopressor support only
  • 40. Steroids  Treat patients who still require vasopressors despite fluid replacement with hydrocortisone 200-300 mg/day, for 7 days in three or four divided doses or by continuous infusion. Grade C
  • 41. Figure 2B, page 867, reproduced with permission from Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
  • 42. Identification of Relative Adrenal Insufficiency Recommendations vary based on different measurements and different cut-off levels  Peak cortisol after stimulation  Random cortisol  Incremental increase after stimulation  Lower dose ACTH stimulation test  Combinations of these criteria
  • 43. Steroids Optional:  Adrenocorticotropic hormone (ACTH) stimulation test (250-µg) Continue treatments only in nonresponders (rise in cortisol ≤9 µg/dl) Grade E
  • 45. Steroids Optional:  Decrease steroid dose if septic shock resolves. Grade E
  • 46. Steroids Optional:  Taper corticosteroid dose at end of therapy. Grade E
  • 47. Immunologic and Hemodynamic Effects of “Low-Dose” Hydrocortisone in Septic Shock Figure 3, page 515, reproduced with permission from Keh D, Boehnke T, Weber- Cartens S, et al. Immunologic and hemodynamic effects of “low dose” hydrocortisone in septic shock. Am J Respir Crit Care Med 2003;167:512-520
  • 48. Steroids Optional:  Add fludrocortisone (50 µg orally once a day) to this regimen. Grade E
  • 49. ADRENALS AND SURVIVAL FROM ENDOTOXEMIA 0 10 20 30 40 50 60 70 80 90 INTACT SHAM ADRNX MEDX DEATH % Adapted from Figure 7, page 437, with permission from Witek-Janusek L, Yelich MR. Role of the adrenal cortex and medulla in the young rats’ glucoregulatory response to endotoxin. Shock 1995; 3:434-439
  • 50. Steroids  Do not use corticosteroids >300 mg/day of hydrocortisone to treat septic shock. Grade A Bone, et al. NEJM 1987; 317-658 VA Systemic Sepsis Cooperative Study Group. NEJM 1987; 317:659-665
  • 51. Thrombin Thrombomodulin Protein C (Inactive) Protein C Activity Blood Vessel Blood Flow ⇒ Protein C Receptor Protein S Human Activated Protein C Endogenous Regulator of Coagulation
  • 52. 35 30 25 20 15 10 5 0 30.8% 24.7% Placebo (n-840) Drotrecogin alfa (activated) (n=850) Mortality(%) 6.1% absolute reduction in mortality Results: 28-Day All-Cause Mortality Primary analysis results 2-sided p-value 0.005 Adjusted relative risk reduction 19.4% Increase in odds of survival 38.1% Adapted from Table 4, page 704, with permission from Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
  • 53. Patient Selection for rhAPC  Full support patient  Infection induced organ/system dysfunction  High risk of death  No absolute contraindications
  • 54. Mortality and APACHE II Quartile APACHE II Quartile *Numbers above bars indicate total deaths 0 5 10 15 20 25 30 35 40 45 50 1st (3-19) 2nd (20-24) 3rd (25-29) 4th (30-53) Placebo Drotrecogin Mortality(percent) 26:33 57:49 58:48 118:80 Adapted from Figure 2, page S90, with permission from Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31[Suppl.]:S85-S90
  • 55. Mortality and Numbers of Organs Failing Percent Mortality 0 10 20 30 40 50 60 1 2 3 4 5 Placebo Drotrecogin Number of Organs Failing at Entry Adapted from Figure 4, page S91, with permission from Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31[Suppl.]:S85-S90
  • 56. Recombinant Human Activated Protein C (rhAPC)  High risk of death  APACHE II ≥ 25  Sepsis-induced multiple organ failure  Septic shock  Sepsis induced ARDS  No absolute contraindications  Weigh relative contraindications Grade B
  • 57. Transfusion Strategy in the Critically Ill Figure 2A, page 414, reproduced with permission from Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417
  • 58. Blood Product Administration Red Blood Cells Tissue hypoperfusion resolved No extenuating circumstances  Coronary artery disease  Acute hemorrhage  Lactic acidosis Transfuse < 7.0 g/dl to maintain 7.0-9.0 g/dL Grade B
  • 59. Blood Product Administration  Do not use erythropoietin to treat sepsis- related anemia. Erythropoietin may be used for other accepted reasons. Grade B
  • 60. Blood Product Administration Fresh frozen plasma • Bleeding • Planned invasive procedures. Grade E
  • 61. Blood Product Administration • Do not use antithrombin therapy. Grade B Warren et al. JAMA 2001; 1869-1878
  • 62. Blood Product Administration  Platelet administration  Transfuse for < 5000/mm3 -  Transfuse for 5000/mm3 – 30,000/mm3 with significant bleeding risk  Transfuse < 50,000/mm3 for invasive procedures or bleeding Grade E
  • 63.
  • 65. 0 5 10 15 20 25 30 35 40 6 ml/kg 12 ml/kg %Mortality ARDSnet Mechanical Ventilation Protocol Results: Mortality Adapted from Figure 1, page 1306, with permission from The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-1378
  • 67. Mechanical Ventilation of Sepsis-Induced ALI/ARDS Reduce tidal volume over 1–2 hrs to 6 ml/kg predicted body weight Maintain inspiratory plateau pressure < 30 cm H20 Grade B
  • 68. Mechanical Ventilation of Sepsis-Induced ALI/ARDS  Minimum PEEP  Prevent end expiratory lung collapse  Setting PEEP  FIO2 requirement  Thoracopulmonary compliance Grade E
  • 69. The Role of Prone Positioning in ARDS  70% of prone patients improved oxygenation  70% of response within 1 hour  10-day mortality rate in quartile with lowest PaO2:FIO2 ratio (≤88)  Prone — 23.1%  Supine – 47.2% Gattinoni L, et al. N Engl J Med 2001;345:568-73; Slutsky AS. N Engl J Med 2001;345:610-2. Kaplan-Meier estimates of survival at 6 months Survival(%) 100 75 50 25 0 30 60 90 120 150 1800 Days Supine group Prone group P=0.65
  • 70. The Role of Prone Positioning in ARDS Consider prone positioning in ARDS when:  Potentially injurious levels of F1O2 or plateau pressure exist  Not at high risk from positional changes Grade E
  • 71. Mechanical Ventilation of Severe Sepsis  Semirecumbent position unless contraindicated with head of the bed raised to 45o Grade C Drakulovic et al. Lancet 1999; 354:1851-1858
  • 72. Mechanical Ventilation of Septic Patients  Use weaning protocol and a spontaneous breathing trial (SBT), at least daily Grade A Ely, et al. NEJM 1996; 335:1864-1869 Esteban, et al. AJRCCM 1997; 156:459-465 Esteban, et al. AJRCCM 1999; 159:512-518
  • 73. Mechanical Ventilation of Septic Patients SBT options • Low level of pressure support with continuous positive airway pressure 5 cm H2O • T-piece
  • 74. Prior to SBT a) Arousable b) Hemodynamically stable (without vasopressor agents) c) No new potentially serious conditions d) Low ventilatory and end-expiratory pressure requirements e) Requiring levels of FIO2 that could be safely delivered with a face mask or nasal cannula Consider extubation if SBT is unsuccessful
  • 75. Sedation and Analgesia in Sepsis  Sedation protocol for mechanically ventilated patients with standardized subjective sedation scale target. • Intermittent bolus • Continuous infusion with daily awakening/retitration Grade B Kollef, et al. Chest 1998; 114:541-548 Brook, et al. CCM 1999; 27:2609-2615 Kress, et al. NEJM 2000; 342:1471-1477
  • 76. Neuromuscular Blockers Avoid if possible Used longer than 2-3 hrs  PRN bolus  Continuous infusion with twitch monitor Grade E
  • 77. The Role of Intensive Insulin Therapy in the Critically Ill At 12 months, intensive insulin therapy reduced mortality by 3.4% (P<0.04) Adapted from Figure 1B, page 1363, with permission from van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67 In-hospitalsurvival(%) 100 0 0 Intensive treatment Conventional treatment Days after admission 80 84 88 92 96 50 100 150 200 250 P=0.01
  • 78. Glucose Control  After initial stabilization  Glucose < 150 mg/dL  Continuous infusion insulin and glucose or feeding (enteral preferred)  Monitoring • Initially q30–60 mins • After stabilization q4h Grade D
  • 79. Renal Replacement Absence of hemodynamic instability  Intermittent hemodialysis and continuous venovenous filtration equal (CVVH) Hemodynamic instability  CVVH preferred Grade B
  • 80.  Bicarbonate therapy not recommended to improve hemodynamics in patients with lactate induced pH >7.15 Grade C Cooper, et al. Ann Intern Med 1990; 112:492-498 Mathieu, et al. CCM 1991; 19:1352-1356 Bicarbonate Therapy
  • 81. Changing pH Has Limited Value Treatment Before After NaHCO3 (2 mEq/kg) pH 7.22 7.36 PAOP 15 17 Cardiac output 6.7 7.5 0.9% NaCl pH 7.24 7.23 PAOP 14 17 Cardiac output 6.6 7.3 Cooper DJ, et al. Ann Intern Med 1990; 112:492-498
  • 82. Deep Vein Thrombosis Prophylaxis Heparin (UH or LMWH) Contraindication for heparin  Mechanical device (unless contraindicated) High risk patients  Combination pharmacologic and mechanical Grade A
  • 83. Primary Stress Ulcer Risk Factors Frequently Present in Severe Sepsis Mechanical ventilation Coagulopathy Hypotension
  • 84. Choice of Agents for Stress Ulcer Prophylaxis H2 receptor blockers Role of proton pump inhibitors Grade C Cook DJ, et al. Am J Med 1991; 91:519-527
  • 85. Consideration for Limitation of Support  Advance care planning, including the communication of likely outcomes and realistic goals of treatment, should be discussed with patients and families. Decisions for less aggressive support or withdrawal of support may be in the patient’s best interest. Grade E
  • 86. Phase 1 Barcelona declaration Phase 2 Evidence based guidelines Paediatric issues Phase 3 Implementation and education Surviving Sepsis
  • 87. Fluid Resuscitation Aggressive fluid resuscitation with boluses of 20 ml/kg over 5-10 min Blood pressure by itself is not a reliable endpoint for resuscitation Initial resuscitation usually requires 40-60 ml/kg, but more may be required
  • 88. Hemodynamic Support  Hemodynamic profile may be variable  Dopamine for hypotension  Epinephrine or norepinephrine for dopamine- refractory shock  Dobutamine for low cardiac output state  Inhaled NO useful in neonates with post-partum pulmonary hypertension and sepsis
  • 89. Therapeutic Endpoints  Capillary refill < 2 sec  Warm extremities  Urine output > 1 ml/kg/hr  Normal mental status  Decreased lactate  Central venous O2 saturation > 70%
  • 90. Other Therapies  Steroids: recommended for children with catecholamine resistance and suspected or proven adrenal insufficiency.  Activated protein C not studied adequately in children yet.  GM-CSF shown to be of benefit in neonates with sepsis and neutropenia.  Extracorporeal membrane oxygenation (ECMO) may be considered in children with refractory shock or respiratory failure.
  • 91. Phase 1 Barcelona declaration Phase 2 Evidence based guideline Phase 3 Implementation and education Surviving Sepsis
  • 92. Sepsis Resuscitation Bundle Serum lactate measured Blood cultures obtained prior to antibiotic administration From the time of presentation, broad- spectrum antibiotics administered within 3 hours for ED admissions and 1 hour for non-ED ICU admissions
  • 93. Sepsis Resuscitation Bundle In the event of hypotension and/or lactate >4 mmol/L (36 mg/dl):  Deliver an initial minimum of 20 ml/kg of crystalloid (or colloid equivalent*)  Apply vasopressors for hypotension not responding to initial fluid resuscitation to maintain mean arterial pressure (MAP) ≥65 mm Hg *See the individual chart measurement tool for an equivalency chart.
  • 94. Sepsis Management Bundle Low-dose steroids* administered for septic shock in accordance with a standardized ICU policy Drotrecogin alfa (activated) administered in accordance with a standardized ICU policy *See the individual chart measurement tool for an equivalency chart.
  • 95. Sepsis Management Bundle  Glucose control maintained ≥ lower limit of normal, but < 150 mg/dl (8.3 mmol/L)  Inspiratory plateau pressures maintained < 30 cm H2O for mechanically ventilated patients.
  • 96. Sepsis Resuscitation Bundle In the event of persistent hypotension despite fluid resuscitation (septic shock) and/or lactate > 4 mmol/L (36 mg/dl):  Achieve central venous pressure (CVP) of 8 mm Hg  Achieve central venous oxygen saturation (ScvO2) of ≥ 70%** **Achieving a mixed venous oxygen saturation (SvO2) of 65% is an acceptable alternative.
  • 97. A clinician, armed with the sepsis bundles, attacks the three heads of severe sepsis: hypotension, hypoperfusion and organ dysfunction. Crit Care Med 2004; 320(Suppl):S595-S597
  • 98. Actual title of painting is “Hercules Kills Cerberus,” by Renato Pettinato, 2001. Painting hangs in Zuccaro Place in Agira, Sicily, Italy. Used with permission of artist and the Rubolotto family.
  • 100. Acknowledgment The SSC is grateful to R. Phillip Dellinger, MD, for his input into creation of this slide kit.

Editor's Notes

  1. This slide set and associated background notes are provided by the Surviving Sepsis Campaign (SSC) as a service to all those interested in furthering the cause of the campaign. Educators, using the slide set for lecture purposes, should select the slides that satisfy content needs and the time constraints of their lecture. Table of Content Slides 1 – 9:Introduction and Background Slides 10 – 85:Recommendations and Rationale Slides 86 – 90:Pediatric Considerations Slides 91 – 98:Phase III, Development of the Sepsis Bundles
  2. The Surviving Sepsis Campaign was initiated in 2002 by the European Society of Intensive Care Medicine, the International Sepsis Forum, and the Society of Critical Care Medicine with the intent to reduce mortality rates in severe sepsis by 25% in 5 years. An open invitation exists for unrestricted education grants from industry to help support this campaign. Thus far, education grants have come from Baxter Bioscience, Edwards Lifesciences, and Eli Lilly and Company.
  3. The campaign was divided into three phases to include the Barcelona declaration, creation of evidence-based guidelines, and implementation in education. Phase 1 began with the issuance of the Barcelona declaration at the European Society of Intensive Care Medicine meeting in Barcelona, Spain in 2002. The declaration proclaimed an attempt by the Surviving Sepsis Campaign to reduce mortality in severe sepsis by 25% in 5 years.
  4. Phase 2 of the campaign was targeted toward the creation of evidence-based guidelines in the management of severe sepsis.
  5. An unprecedented 11 international organizations, with interest and expertise in the management of the septic patient, came together as co-sponsors of the evidence-based guidelines.
  6. Forty-seven committee members from the 11 organizations worked over a year to finalize the guidelines. Of note, the decision was made to exclude from committee selection primary investigators who had recently participated in positive trials with implications for septic patients. Although this excluded leaders in the field, it minimized perception of influence on the guidelines.
  7. The guidelines were published in both Critical Care Medicine and in Intensive care Medicine, and are available on-line.
  8. The grading system built upon an adaptation from Sackett et al., which had previously been used by the Society of Critical Care Medicine in the Pulmonary Artery Consensus Conference published in Critical Care Medicine. The rationale for using this particular grading system was that the current guidelines built upon a document published as a supplement in Intensive Care Medicine in 2001 by the International Sepsis Forum which had used this grading system.
  9. The recommendations are listed in a logical order of encounter with the septic patient and the order does not imply listing by importance. Likewise, the grading system allows higher grades where clinical trials have been performed and do not necessarily reflect the committee’s implication of importance, as some of the more important recommendations received a grade E (expert opinion) since no clinical trials have been performed to validate these recommendations.
  10. The initial resuscitation of the patient is of utmost importance and frequently occurs in the emergency department or on hospital wards.
  11. The physiological changes occurring in patients with severe sepsis and septic shock are myriad and include changes that are clearly detrimental such as decreased contractility of the left and right ventricle, increased venous capacitance, increased pulmonary vascular resistance, and capillary leak. Increased ventricular compliance and sinus tachycardia are likely adaptive responses allowing the ventricle to maintain, and even manifest increased cardiac input, following volume resuscitation in despite decreased contractility. The decreased arteriolar resistance may also be adaptive, although when profound, produces detrimental and potentially lethal hypotension.
  12. The recommendations for initial resuscitation are centered around the Rivers trial (above) of early goal-directed therapy, which showed significant improvement in (a) hospital mortality, (b) 28-day mortality, and (c) 60-day mortality.
  13. The recommendation for initial resuscitation in patients with sepsis induced hypoperfusion, defined as hypotension (requiring vasopressors or lactic acidosis) is targeted toward the Rivers’ protocol.
  14. Previous literature supports equivalent tissue perfusion (measured by five different tissue perfusion parameters) between 65 mm Hg and 85 mm Hg of mean arterial blood pressure with norepinephrine in septic shock.
  15. The recommendations for initial resuscitation include those goals targeted in both the standard and early goal-directed therapy (EGDT) groups of the Rivers’ study to include CVP  8–12 mm Hg, mean arterial pressure  65 mm Hg, and a goal of urine output  .5 ml/kg/hr, as well as a central venous (superior vena cava) O2 saturation of  70%, the additional target in the EGDT group. In addition, intubation and mechanical ventilation was performed if necessary to maintain an arterial saturation of 93% or greater.
  16. Again, based on the Rivers study, if volume resuscitation fails to achieve a mixed venous O2 sat of 70% or greater, packed red blood cells to a hematocrit of 30% and/or dobutamine to a max of 20 g/kg/min to achieve this goal is recommended.
  17. Appropriate cultures should be obtained from all potential sites of infection. In addition, a minimum of two blood cultures, of which at least one should be percutaneous and one from each vascular access site in place for  48 hours should be obtained.
  18. Although high-level evidence is not currently available, the early administration of intravenous antibiotics is a high priority in patients with severe sepsis, and should begin within the first hour of recognition of severe sepsis.
  19. Covering broad initially in patients with severe sepsis to include one or more drugs active against all likely bacterial or fungal pathogens is recommended. It is important to consider microorganisms susceptibility patterns in the community and hospital, which may vary from region to region.
  20. Equally important as broad initial coverage is the willingness of the physician to reassess antimicrobial regimen at 48–72 hours in an attempt to use microbiologic and clinical data to narrow the antibiotic coverage. In addition, if noninfectious causes are now thought to have likely been the reason for the patient’s deterioration and cultures are negative, antibiotics should be discontinued. This is important to prevent emergence of resistant organisms, which has become a major problem, as well as to reduce toxicity and cost.
  21. Early emphasis on identification of source control problems is a high priority to avoid morbidity and mortality. All patients should be evaluated for a focus of infection, amenable to source control measures, to include abscess drainage or tissue debridement. Following stabilization the clinician should move rapidly to achieve this goal. The potential physiologic upset of the measure chosen for source control should be considered (for example percutaneous drainage may be preferred over operative theatre intervention). All intravascular access devices that may be a source of infection should be removed and, in the absence of identified site, should be assumed to be a potential site.
  22. This picture demonstrates a 38-year-old man with pharyngitis who presents with high fever, leukocytosis, hypotension, elevated BUN/creatinine, and early evidence of coagulopathy who now has redness and swelling of the anterior neck and chest pain.
  23. An EKG obtained in this patient demonstrates a diffuse ST segment elevation (or PR depression) diagnostic of pericarditis, and in this case indicating the presence of mediastinitis requiring urgent operative drainage of the mediastinum in order to prevent mortality.
  24. Colloid or crystolloid resuscitation is considered equal. Colloids are associated with less peripheral edema and crystolloids with considerable less cost.
  25. Meta analyses reveal no difference between crystalloids and colloids in general populations of critically ill patients.
  26. The initial fluid resuscitation and ongoing resuscitation of patients with severe sepsis and tissue hypoperfusion is built around fluid challenges delivered over 30 minutes using either 500 – 1000 ml of crystolloid or 300 – 500 ml of colloids. These should be repeated based on response until tissue hypoperfusion is relieved or there is evidence of intolerance of fluid resuscitation, i.e. volume overload.
  27. Norepinephrine or dopamine, as combined inotrope/vasopressors (to match the sepsis-induced decrease in contractility and systemic vascular resistance) are considered equal choices as the initial vasopressor of choice. It is important to remember that vasopressors should be utilized not only when fluid resuscitation fails to reverse hypotension, but also during fluid resuscitation to maintain minimally adequate blood pressure while fluid resuscitation is administered in attempts to decrease vasopressor requirement.
  28. Considerable data (such as that shown above) indicates that epinephrine, although a combined inotrope/vasopressor, is not the best initial vasopressor of choice because of concerns with decrease in splanchnic blood flow. The study above comparing dopamine, norepinephrine, and epinephrine in moderate shock, and norepinephrine and epinephrine in severe shock supports epinephrine induced decrease in splanchnic blood flow.
  29. Although low-dose dopamine was routinely used for years in hopes of renal protection in patients with acute tissue hypoperfusion and multi-organ system dysfunction, and in combination with vasopressor level blood pressure support, it is now clear that low-dose dopamine does not improve outcome in these patient groups.
  30. Patients requiring vasopressors should have an arterial catheter in place so that sudden changes in blood pressure can be monitored and vasopressors can be titrated more easily. This may not be practical, however, during initial resuscitation in the emergency department or on hospital wards.
  31. Vasopressin levels are elevated during the initial presentation of septic shock and then decrease to basal levels over the next 48 to 96 hours. Since vasopressin levels are expected to be a normal body response to hypotension, this occurrence has been labeled as relative vasopressin deficiency and has led to the use of vasopressin in patients with septic shock.
  32. When patients with septic and cardiogenic shock are maintained at the same mean arterial blood pressure with vasopressors, it is noted that cardiogenic shock patients maintain elevated vasopressin levels while patients with septic shock over time have lower levels that approach baseline. In addition, prospective, randomized, blinded studies have demonstrated the potential for low-dose vasopressin to decrease or eliminate requirements of traditional pressors. However, as a pure vasopressor/vasopressin would be expected to decrease stroke volume and cardiac output as traditional vasopressors are replaced. This may be problematic, particularly in patients with significant decrease in ejection fraction and low baseline cardiac outputs.
  33. Although vasopressin has been demonstrated in some studies to improve renal function, there are other studies that raise concern about preservation of splanchnic perfusion. Vasopressin should not be considered a replacement for norepinephrine or dopamine as a first-line agent in septic shock. However, it may be considered in refractory shock despite high-dose conventional vasopressors or when high vasopressor requirements continue for 48 hours or longer. If used, it should be administered at very low doses, not to exceed .04 units/min in adults. Higher doses may be associated with coronary or mesenteric ischemia.
  34. This slide demonstrates radionuclide angiography in a patient during septic shock and following recovery. The top left panel shows end-diastole and demonstrates increased diastolic size of the ventricles (increased compliance), which is thought to be an adaptive mechanism. The top right image shows end-systole in this patient demonstrating a very low ejection fraction (little change in chamber size compared to end-diastole). The bottom two frames following recovery demonstrate a decrease in end-diastole volume, smaller ventricle at end systole and therefore significant improvement in ejection fraction.
  35. A significant contractility decrease may occur in some patients with septic shock. When cardiac output is being measured (either invasively or noninvasively) and a low cardiac output is present despite adequate fluid resuscitation, the consideration of adding dobutamine to raise cardiac output to a normal range is appropriate. It is important when this is done to continue to titrate vasopressors to maintain a mean arterial pressure of  65 mm Hg.
  36. Since patients with septic shock typically have a lactic acidosis, and since lactic acidosis is associated with a “oxygen debt”, the the possibility of improving outcome by reversing oxygen debt by producing supranormal oxygen delivery has led to multiple clinical trials in this area. Unfortunately, none of these trials have shown clinical outcome benefit, and one study (Hayes) suggested harm when very high level inotropes were used to drive oxygen delivery to supranormal levels. Therapy should therefore be targeted toward reversing clinical signs of tissue hypoperfusion and not toward an arbitrarily pre-defined level of oxygen delivery.
  37. The largest randomized prospective trial done to study the effect of stress-dose steroids in septic shock is the “French multi-center trial”, which targeted, “apriori,” patients who did not respond to ATCH stimulation as the group that would likely benefit from steroid therapy (slide shows results in that group). This group represented 77% of the population, and in this group significant improvement in survival by Kaplan-Meier curve with logistic regression adjustment for other variables influencing survival was shown.
  38. Single center studies also support significant clinical benefit as to morbidities and/or mortality.
  39. The Annane, Bollaert and Briegel studies used a variety of doses, routes of administration, and stop and tapering rules, but all three studies supported the ability of low-dose (stress-dose), i.e., 200-300 mg of hydrocortisone a day to improve clinical outcome. Although the Annane study has the highest evidence based support since it was a multicenter study with significant p-value on a priori survival cure logistic regression adjusted analysis, this study had a very rigorous entry requirement, requiring that patients be hypotensive despite therapy for at least an hour to be included. The Bollaert and Briegel studies, although smaller, suggest benefit of steroids in septic patients with vasopressor requirement only, a more commonly encountered group in clinical practice.
  40. The utilization of stress dose (“low-dose”) steroids is recommended for the treatment of patients with severe sepsis who continue to require significant amounts of vasopressors despite adequate fluid replacement. It should be noted that this recommendation includes a range of daily steroid dosing as well as alternative dosing methods to include intermittent dosing or continuous infusion. The rationale behind the construction of this recommendation is that it is a hybrid of regimens from the Ananne study, the Bollard study and the Briegel study.
  41. The apriori analysis group in the 2002 Annane study were patients who were non-responders to ACTH stimulation, i.e., relative adrenal insufficiency (see previous slide). This patient population was defined based on a previous Annane study showing that septic shock patients who were unable to raise their cortisol by 10 or more at either 30 or 60 minutes following 250 g ACTH stimulation, were at high risk for death. There was no evidence of benefit in non-responders (as shown above).
  42. Experts disagree on the best way to characterize relative adrenal insufficiency. In addition to the criteria used by Annane (incremental increase after high-dose ACTH (250 g) stimulation), other investigators have used random cortisol level, peak cortisol after stimulation, lower dose ACTH stimulation test, and combinations of these criteria.
  43. The use of ACTH stim test to define non-responders (post-stimulation cortisol 9 g/dl) as those who will have steroids continued is optional. If this approach is taken, steroid therapy is discontinued in responders.
  44. If the ACTH stimulation test is to be performed dexamethasone can be initiated pending performance of the ACTH stim test, as unlike hydrocortisone or methylprednisolone, it does not have cortisol-like metabolites, which interfere with the cortisol assay.
  45. Another option during steroid therapy is to taper and then discontinue steroids earlier when shock rapidly resolves (as opposed to a set course of 7 days).
  46. Corticosteroid dose may also be tapered at the end of 7-day therapy to avoid possible rebound effect of inflammation and decrease a blood pressure (see next slide).
  47. In this study by Keh and colleagues patients were randomized to low-dose steroids or placebo and then crossed over after three days. The patients going from steroids to placebo exhibited a significant pro-inflammatory rebound associated with increased vasopressor requirements.
  48. A final option for steroid therapy of septic shock includes the addition of fludrocortisone (a pure mineralocorticoid) . Fludrocortisone was utilized in the Annane study, but not in the Bollaert or Briegel studies. Hydrocortisone does have significant mineralocorticoid activity, although fludrocortisone is a pure mineralocorticoid. (See next slide.)
  49. In a study by Witek-Janusek and colleagues, utilizing a rodent preparation of septic shock, a comparison was made among effect of intact adrenal gland, ablation of adrenal cortex function (ADRNX) and ablation of adrenal medullary function (MEDX) on survival. The ablation of the glucocorticoid producing cortex produced a significant increase in mortality, whereas ablation of the medulla (mineralocorticoids production) had no significant effect on survival, and was similar to the intact adrenal (see above). This type of animal evidence supports the importance of glucocorticoids and not mineralocorticoids in ameliorating sequelae of septic shock.
  50. Based on several studies demonstrating lack of efficacy when high-dose corticosteroids (up to a gram of methylprednisolone) are given during the first 24 hours of severe sepsis and septic shock, the use of corticosteroids greater than 300 mg a day is not recommended.
  51. A key modulator of the thrombin triggered coagulation response to sepsis is the activation of protein C. Inactive protein C zymogen is activated by a combination of the endothelial surface receptors (thrombin/thrombomodulin receptor, and the protein C receptor). In patients with severe sepsis, these endothelial receptors are stripped off the surface of the endothelium and can be identified in the circulation leading to decreased capability for activating protein C.[1] Once protein C is activated protein S is a co-factor for amplification of activity. 1.Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408-416
  52. Activated protein C when administered in a blinded, randomized fashion to over 1600 patients with severe sepsis and septic shock produced a 6.1% absolute reduction in mortality.
  53. In considering patient selection for rhAPC, the patient should be full support, have an infection induced organ system dysfunction that is associated with a high risk of death, and have no absolute contraindications to drug use (significant risk of fatal hemorrhage such as previous hemorrhagic stroke or recent visceral trauma).
  54. The FDA labeling for rhAPC indicates use for patients with sepsis induced organ dysfunction associated with a high risk of death, such as APACHE II of 25 or greater. This is based on subset analysis of the four APACHE II quartiles in the rhAPC clinical trial showing that most of the benefit occurred in patients with APACHE II of 25 or greater.
  55. The European regulatory authority lists multiple organ failure as the indication for rhAPC therapy in severe sepsis. This is based on subset analysis indicating that patients with multiple organ failure are most likely to benefit.
  56. The SSC recommendation lists four patient findings that would be linked to high risk of death for which rhAPC is recommended. In addition to no absolute contraindications, relative contraindications should also be weighed.
  57. In 1999, Herbert al. published a large study that randomized a general population of ICU patients to receive either restrictive transfusion strategy in which transfusion occurred (1) when the hemoglobin decreased to less than 7g/dl to maintain a 7–9 g/dl versus (2) transfusing when the hemoglobin decreased to less than 10 g/dl to maintain 10–12 g/dl. There was no statistically significant difference in mortality in the two ICU patient groups, with a trend in survival favoring the restrictive transfusion strategy.
  58. Once tissue hypoperfusion has resolved, and in absence of the extenuating circumstances as listed, the transfusion threshold should be as it was in the restrictive group in the Herbert study.
  59. Although erythropoietin may be used for other accepted reasons such as chronic renal failure, it should not be used to treat sepsis related anemia in the absence of these other indications.
  60. Fresh frozen plasma should be reserved for the bleeding patient or for planned invasive procedures. In those circumstances targeting an INR of 1.5 or less would be appropriate.
  61. Antithrombin therapy is not recommended. One clinical trial performed in patients with severe sepsis demonstrated no benefit.
  62. An absolute threshold is recommended for transfusion of platelets in all patients with severe sepsis, a second range when there is significant bleeding risk, and a third threshold in the presence of bleeding or when invasive procedures are planned.
  63. This chest radiograph shows a patient with ARDS characterized by diffuse bilateral infiltrates.
  64. Sepsis is the most frequent cause of acute lung injury and acute respiratory distress syndrome (ARDS). Acute lung injury is the most common system dysfunction in sepsis and is associated with significant morbidity and mortality. Patients with severe lung injury, i.e., sepsis induced ARDS almost always require mechanical ventilation, and many patients with acute lung injury are also mechanically ventilated.
  65. The ARDSnet trial compared 6 ml/kg ideal body weight vs. 12 ml/kg ideal body weight (low tidal volume/high tidal volume comparison). The low tidal volume group demonstrated a significant decrease in mortality.
  66. Measurement of inspiratory plateau pressure allows estimation of the end inspiratory alveolar pressure as a marker of lung inflation. A .5 second end inspiratory typically allows this measurement.
  67. The recommendation for mechanical ventilation of sepsis induced ALI/ARDS is to reduce tidal volume (TV) over 1 to 2 hours to 6ml/kg predicted body weight (PBW—formula available on the ARDSnet and SSC websites) starting at 8ml/kg. In addition, inspiratory plateau pressure should be measured and maintained &amp;lt; 30 cm H2O. This may require further reduction of TV to as low as 4.0 ml/kg/PBW.
  68. In addition to avoiding lung overinflation during mechanical ventilation of ARDS by limiting tidal volume, it is also important to institute a minimum amount of PEEP that will prevent end-expiratory lung collapse. Because of the increased lung water and associated decreased compliance, end-expiratory lung collapse occurs at low levels of PEEP. Repeated closing and opening of lung with tidal excursion is thought to produce sheer force injury. There are two potential ways of setting minimal PEEP. One is to utilize the ARDSnet table (web site address) another more sophisticated method, not usually practical in the typical hospital environment, is measuring thoracopulmonary compliance and setting PEEP in an area of optimal compliance.
  69. Despite significant improvement in oxygen in 70% of patients proned in one large study there was no difference in clinical outcome through a 180 days. However, in patients with the severest of hypoxemia there was a suggestion of benefit.
  70. Pending additional clinical trials prone positioning remains unproven as a modality that will alter outcome in ARDS. However, based on the significant improvement in physiology with proning as well as improvement in oxygenation, the committee recommends that it be considered in ARDS patients who have potentially injurious levels of F1O2 or plateau pressure despite optimization of traditional mechanical ventilation. Patients at high risk from proning such as (a) hemodynamic instability, (b) placement of multiple anterior invasive devices/tubes/lines, or (c) morbid obesity are likely not good candidates for prone positioning. In that circumstance and in the presence of life-threatening hypoxemia, inhaled nitric oxide therapy could be considered as salvage therapy.
  71. In order to decrease the incidence of ventilator acquired pneumonia, the semirecumbent position should be utilized, unless contraindicated, in all mechanically ventilated septic patients. Although 30°–45° is often mentioned as the target elevation, 45° has the best supportive evidence.
  72. In mechanically ventilated septic patients, a weaning protocol should be in place to evaluate on a daily basis the likelihood of weaning and extubation. Protocol criteria should exist for preforming a spontaneous breathing trial at least daily.
  73. Options for spontaneous trial include low-level pressure support with CPAP of 5 or T-piece (humidified gas delivered to endotracheal tube off mechanical ventilator support).
  74. Certain criteria should be assessed and met prior to spontaneous breathing trial performance. If a spontaneous breathing trial is successful (typically frequency/tidal volume ratio &amp;lt; 105) after 30-60 minutes, serious consideration should be given for extubation.
  75. Most patients mechanically ventilated with severe sepsis require some degree of sedation and analgesia. However, overuse of these drugs leads to prolonged need for mechanical ventilation. It is therefore important to titrate sedation and analgesia to the minimal effective dose. This is likely best done using bolus administration so that the drug is only given when bedside evaluation indicates a lack of sedation or analgesia. When continuous infusion is needed there should be daily awakening and retitration to minimally effective doses to avoid oversedation and tissue accumulation of sedating agents.
  76. Neuromuscular blockade (NMB) is being used less and less in mechanically ventilated patients with severe sepsis. NMB beyond the initial stabilization period is associated with a significant incidence of prolonged neuromuscular blockade following discontinuation of NMB. Neuromuscular blockade should be avoided if possible. When utilized longer then 2–3 hours, NMB administration should be either (a) PRN bolus with drug administration only when a clearly identified patient need arises or (b) by continuous infusion with a twitch monitor. The twitch monitor is kept at a minimum of 2 or more twitches following a train of four delivery of electric signals. Neuromuscular blockade is primarily used to control patient respiratory rate (equal to or less than set ventilator rate). When patient rate control can be achieved with four out of four twitches that is optimal.
  77. Results of the van den Berghe trial demonstrated an impressive improvement in survival with intensive glycemic control. Patients admitted to SICU mechanically ventilated All patients received 200–300 g glucose/day on admission and continuous infusion intravenous insulin as needed to achieve target glucose level. – Conventional: titrate glucose to 180–200 mg/dL –Intensive: titrate glucose to 80–110 mg/dL TPN or parenteral fluid within 24 hours of admission with 60% to 80% glucose calories
  78. The SSC recommendation uses a less stringent glucose threshold then that used by van den Berghe et al., recommending glucose be maintained &amp;lt; 150 mg/dl. Many hospitals may have difficulty securing the intense bedside resources needed to maintain levels between 80 and 110. Finney et al. also demonstrated improved outcome in critically ill patients when glucose was maintained at 110-145 mg/dl (JAMA 2003; 290:2041-2047) It is important that patients who are receiving continuous infusion insulin also be receiving glucose in some form, either TPN, enteral or peripheral glucose infusion. Enteral nutrition is the preferred method of glucose delivery. The initial monitoring will need to be more intense requiring 30–60 minute monitoring. After glucose stabilization is achieved monitoring may be extended to 4 hours.
  79. In the absence of hemodynamic instability intermittent hemodialysis and continuous venovenous hemofiltration (CVVH) offer equal clinical outcome effects. Because intermittent hemodialysis is difficult to maintain in the presence of hemodynamic instability, CVVH is preferred in that circumstance.
  80. Literature supports that in patients with type 1 lactic acidosis (cellular hypoxia) and pH of 7.15, there is no hemodynamic benefit associated with pH correction. Presence of lactate acidosis indicates cellular hypoxia and anaerobic metabolism. Correcting the pH does not alter the hypoxic cellular state.
  81. Cooper and colleagues compared equimolar amounts of sodium bicarbonate and normal saline in patients with vasopressor requiring lactic acidosis (pH range down to 7.15 with mean 7.23) and demonstrated that although pH was significantly increased with bicarbonate versus normal saline there was no difference in cardiac output. There was also no difference between the two groups as to weaning of vasopressors.
  82. Numerous clinical trials containing significant numbers of sepsis patients have demonstrated ability of DVT prophylaxis to decrease incidence of deep vein thrombosis and pulmonary embolism. Either unfractionated heparin or low molecular heparin is recommended. In patients with contraindication for heparin, mechanical compression devices of the lower extremities are recommended unless there is contraindications to compression device, i.e. severe peripheral vascular disease or leg injury. High risk patients should have combination pharmacologic and mechanical therapy considered.
  83. Patients with severe sepsis frequently have literature identified risk factors for stress ulcer bleeding including mechanical ventilation, coagulopathy and hypotension.
  84. Stress ulcer prophylaxis is recommended and H2 receptive blockers are the therapy of choice. Proton pump inhibitors have been demonstrated to show equivalence in raising stomach pH although no clinical studies have been performed.
  85. Many patients with severe sepsis and septic shock have terminal illnesses with short expected life spans. In these patients the highly unlikely benefit of therapy and the potential discomfort associated with aggressive therapy warrants serious consideration for limitation of support with implementation of comfort care, emotional support to the patient and family, and pain control.
  86. Although there is limited data available from prospective clinical trials in pediatric septic patients, there are considerable differences in the pathophysiology of pediatric sepsis that warrants comment.
  87. Fluid resuscitation of pediatric patients is weight based and aggressive, with initial resuscitation of 20ml/kg and often up to 40–60ml/kg required during the initial resuscitation. Blood pressure itself is not a reliable endpoint for resuscitation. Physical exam, urine output, and pulse response are the primary response monitors.
  88. The hemodynamic profile of pediatric sepsis is quite variable. Dopamine with its combined inotrope and vasopressor characteristics is recommended for pediatric hypotension because of the tendency for a lower cardiac output in this patient population. Epinephrine or norepinephrine are then added for dopamine refractory shock. When cardiac output is measured, dobutamine is recommended for low cardiac output states. Inhaled nitric oxide may be useful in neonates who are septic with post-partum pulmonary hypertension.
  89. Physical exam findings indicating successful resuscitation include a capillary refill &amp;lt; 2sec, warm extremities, and normal mental status. Other objective targets include urine output &amp;gt; 1ml/kg/hr and normalization of lactate, and as in the adult, central venous O2 sat 70%.
  90. As in adults, steroids are recommended for children with catecholamine resistance and suspected or proven adrenal insufficiency. Activated protein C has not been studied in pediatric severe sepsis. Unlike adults GM-CSF has been shown to be of benefit in neonates in circumstances of neutropenia and sepsis. ECMO, not recommended in adults, may be useful in children with refractory shock or respiratory failure.
  91. The third and most important phase of the Surviving Sepsis Campaign is implementation and education, since only behavior change will effect clinical outcome improvement. The creation of guidelines, although an important component of the process, does not in itself change behavior.
  92. The SSC sepsis change bundle description and process is covered in depth on the SSC/IHI web site accessible through either of the two web sites above. There is a direct link available from home page of the SSC web site. From the home page of the IHI web site select Topics  Critical Care  Sepsis.